Iovance Biotherapeutics, Inc. (IOVA) — Stock Price, Chart & Analysis
Iovance Biotherapeutics, Inc. (IOVA) is a Healthcare stock currently trading at $9.26, up 126.96% on the day. It carries a market capitalization of $4.82B. Over the past 52 weeks, IOVA has traded between $1.76 and $10.98. Iovance Biotherapeutics, Inc. does not currently pay a regular dividend. View the live IOVA chart, technical opinion, analyst ratings, fundamentals and latest news below.
Iovance Biotherapeutics, Inc. (IOVA) key data
| Price | $9.26 |
| Change (today) | +126.96% |
| Previous close | $4.08 |
| Market cap | $4.82B |
| EPS (TTM) | $-0.72 |
| 52-week high | $10.98 |
| 52-week low | $1.76 |
| Beta | 0.83 |
| Avg. volume | 16.71M |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Iovance Biotherapeutics, Inc. (IOVA)
How much does one share of Iovance Biotherapeutics, Inc. cost?
As of the latest update, one share of Iovance Biotherapeutics, Inc. (IOVA) trades at $9.26 (+126.96% today).
What is Iovance Biotherapeutics, Inc.'s market cap?
Iovance Biotherapeutics, Inc. has a market capitalization of approximately $4.82B.
What is Iovance Biotherapeutics, Inc.'s earnings per share (EPS)?
Iovance Biotherapeutics, Inc.'s trailing twelve-month EPS is $-0.72.
Does Iovance Biotherapeutics, Inc. pay a dividend?
Iovance Biotherapeutics, Inc. does not currently pay a regular dividend.
What is Iovance Biotherapeutics, Inc.'s 52-week trading range?
Over the past year, IOVA has traded between $1.76 and $10.98.
What is the analyst price target for Iovance Biotherapeutics, Inc.?
The mean analyst price target for Iovance Biotherapeutics, Inc. is $10.22. This is informational only and not investment advice.
Latest Iovance Biotherapeutics, Inc. (IOVA) news
- Why Did Iovance Biotherapeutics (IOVA) Move Today?News · Sep 19, 2026
- Iovance Biotherapeutics (IOVA) Is Up 19.2% After Record Q2 Amtagvi Revenue And TIL Pipeline ExpansionNews · Sep 19, 2026
- Iovance Maps TIL Therapy Expansion After Record Revenue and Margin GainsNews · Sep 19, 2026
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)News · Sep 18, 2026
- This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September RallyNews · Sep 17, 2026
- IOVA Flags Year-End Data Slate After Record Amtagvi Quarter, Highlights ‘Clear Line Of Sight To Profitability’News · Sep 15, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live IOVA dashboard…